Comparison of Drying Techniques to Produce Stable and Bioavailable Encapsulated ACE-2 Nanoparticles
<b>Background/Objectives:</b> COVID-19 infection continues globally, with frequent emergence of unfamiliar SARS-CoV-2 variants acting to impair immunity. The competitive binding of SARS-CoV-2 spike proteins and angiotensin-converting enzyme 2 (ACE-2) can decrease the binding of the virus on native ACE-2 receptors on healthy human cells. It remains a practical approach to lessen viral spread. In this study, a method to encapsulate ACE-2 in the form of chitosan/tripolyphosphate cross-linked nanoparticles (NPs) was developed with emphasis placed on the best dehydration method to secure functional ACE-2 nanoparticles. <b>Methods:</b> Methods: Preparation conditions were assessed by varying pH (4.0-6.5) and the ratio between chitosan and ACE-2 mixing ratios (1:1, 1.5:1, 2:1, 2.5:1, and 3:1). The formulated NPs were then dehydrated using different approaches that included spray-drying (SD), freeze-drying (FD), and spray-freeze drying (SFD) and used varying mannitol concentrations (0, 1:1, and 5:1 of total weight). The mannitol was served as a cryoprotectant in this study. <b>Results:</b> The best formulation achieved used a pH 5.5 with a mixing chitosan-ACE-2 ratio of 2:1, where ACE-2-loaded NPs had an average particle size of 303.7 nm, polydispersity index (PDI) of 0.21, encapsulation efficiency (EE) of 98.4%, and ACE-2 loading content (LC) of 28.4%. After reconstitution, all SD samples had a relatively low yield rate, but the ACE-2 NPs dehydrated specifically using SFD required a lower amount of added mannitol (1:1 of its total weight) and produced a higher yield rate (<i>p</i> < 0.05) and similar PDI and EE values, along with relatively good particle size and LC. This formulation also produced a high ACE-2 release and uptake in differentiated Caco-2 cells, thus representing an effective ACE-2 encapsulation procedure for use with dry powders. <b>Conclusions:</b> This work showed that spray-freeze drying was the best method to dehydrate ACE-2 NPs, using less cryoprotectant to create a significant advantage in terms of greater loading capacity with lower additive requirements.
Authors
- David D. Kitts (ORCID: https://orcid.org/0000-0001-6572-4008)
- Yigong Guo
- Alberto Baldelli (ORCID: https://orcid.org/0000-0002-6296-5460)
- Anika Singh (ORCID: https://orcid.org/0000-0002-0935-4417)
- Anubhav Pratap‐Singh (ORCID: https://orcid.org/0000-0003-1752-0101)
- Dai Shi (ORCID: https://orcid.org/0000-0002-6600-4325)
Institutions
- University of British Columbia (CA)
- British Columbia Institute of Technology (CA)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2025-04-21
- DOI
- https://doi.org/10.3390/pharmaceutics17040537
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Sciences and Engineering Research Council of Canada